Minor
LIMIT · Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Primary completion date changed from estimate of Nov 13, 2026 to Jul 30, 2026
Ravi Amaravadi, MDPhase 1/2 NCT04464759 Registry history of NCT04464759 on ClinicalTrials.gov (opens the registry)